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Abstract 
In recent years, researchers have been focused on study of somatopsychic disorders often found in COPD 
patients. There are various types of mental disorders in COPD patients. However, psychic changes such 
as depression and anxiety are often found in COPD patients with comorbid mental disorders. 
Unfortunately, none of the COPD patient management guidelines currently offer a detailed screening 
plan to determine presence/absence of concomitant depression and/or anxiety, or any methods for 
verification of these somatopsychic disorders 
Aim: to identify the questionnaire which can best help detect COPD patients with somatopsychic 
disorders. 
Materials and Methods: we have examined 56 COPD patients. Patients examination included general 
clinical methods, questionnaires for detecting of mental disorders (PHQ-9, HADS, BDI-SF, STAI), 
psychiatrist examination. 
Results: the following types of somatopsychic disorders have been diagnosed for COPD patients 
examined by a psychiatrist, not only depression and/or anxiety.  
ROC-analysis allowed us to determine that the results received with the HADS had the greatest 
diagnostic value for detection of somatopsychic disorders in COPD patients. This questionnaire has some 
other advantages over the rest of the scales. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a multisystem condition with multiple 
comorbidities [1-5]. They affect the severity of COPD aggravating symptoms, increasing the 
number of exacerbations and hospitalisations, worsening quality of life, and can lead to an 
increased risk of death [6-11]. In recent years, researchers have been focused on study of 
somatopsychic disorders often found in COPD patients [12-18]. 
There are various types of mental disorders in COPD patients who demonstrate the signs of 
somatopsychic conditions: high levels of neuroticism, high state anxiety and trait anxiety, 
depression, dysthymia, substance abuse, asthenia, anxiety syndrome, psychoorganic syndrome, 
hypochondria, and cognitive disorders [19, 20, 21, 22]. However, psychic changes such as 
depression and anxiety are often found in COPD patients with comorbid mental disorders [6, 9, 
12-15, 17, 23, 24]. 
The data on prevalence of depression in COPD patients vary significantly: between 7% and 
80% according to various researchers [25], and prevalence of anxiety disorders can range from 
10% to 100% [9].  
The majority of studies use the syndrome-based approach, including analysis of patient 
questionnaires designed to determine presence and/or severity of depression and anxiety. This 
discrepancy in data collected by various researchers can be often explained by their use of 
different questionnaire methods. The nosological approach, i.e. verification of somatopsychic 
disorders by a psychiatrist, is used less often. 
Though the methods of COPD diagnosis and treatment are being improved all the time, 
detection of somatopsychic disorders in COPD patients remains an important issue. 
Unfortunately, none of the COPD patient management guidelines currently offer a detailed 
screening plan to determine presence/absence of concomitant depression and/or anxiety, or any 
methods for verification of these somatopsychic disorders [26, 27, 28]. Potential tools to detect 
depression and anxiety in patients with this condition have not been studied yet [29]. 
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No particular questionnaire used to detect depression and 
anxiety has proven to be better than others in terms of 
accuracy, reliability or detection of depression and anxiety 
disorders in COPD patients [9]. 
The mental status examination is the only way to verify 
diagnosed psychic disorders in COPD patients. However, is 
impossible in practical medicine to arrange that 
somatopsychic disorders are detected in COPD patients by a 
psychiatrist. The questionnaire methods are a simple, quick 
and cheap way to detect somatopsychic changes, however, the 
vast majority of such questionnaire are designed to detect 
depression or anxiety but no other disorders. Yet, it is known 
that high scores received by using any of the questionnaires 
generally indicate the presence of a mental disorders [30, 31]. 
Therefore, the questionnaire methods can be used for 
screening to identify patients who are more likely to require 
psychiatric consultation. 
In view of the above, the aim of our study was to identify the 
questionnaire which can best help detect COPD patients with 
somatopsychic disorders. 
 
Materials and Methods 
We have studied 56 COPD patients (46 men (82.1±5.1%); 
10 women (17.9±5.1%); mean age — 63.9±1.0 years; forced 
expiratory volume in one second (FEV1) — 51.9±2.2% of the 
predicted value; COPD Assessment Test (CAT) mean score 
— 15.7±1.0). 
Clinical diagnosis of COPD was formulated in accordance 
with Order No.555 issued by the MOH of Ukraine on 
27/06/2013 [6]. 
All patients have had a stable phase of the disease for at least 
two previous months and have been treated as required by 
Order No.555 issued by the MOH of Ukraine on 27/06/2013 
[6]. 
All patients signed an informed consent form prior to their 
participation in the study. 
Patient examination included general clinical methods (such 
as collection of complaints, disease and life history data), 
assessment of clinical symptoms, including by using the CAT 
[6, 10]. 
The study was conducted in two phases. 
During the first phase, patient mental examination was 
conducted with the Patient Health Questionnaire (PHQ-9) [32, 
33], Hospital Anxiety and Depression Scale (HADS) 
recommended for detection of depression (HADS-depression) 
and anxiety (HADS-anxiety) in patients with somatic 
complaints [32, 34], and Beck Depression Inventory-Short Form 
(BDI-SF)) [35], State-Trait anxiety Inventory to assess STAI-
state anxiety and STAI-trait anxiety, respectively [19, 12, 36]. 
During the second phase, all patients had final mental state 
examination by a psychiatrist who used clinical anamnestic, 
psychopathological and psychodiagnostic methods [32]. 
Statistical analysis of the data collected during the study was 
performed by using ROC-analysis. ROC-analysis was 
performed and ROC-curves were constructed in MedCalc 
software, Version 16.4.3, publicly available on the 
developer’s official website. 
The difference between references was considered significant 
at p<0.05 (5%). 
 
Results and Discussion 
The following types of somatopsychic disorders have been 
diagnosed for COPD patients examined by a psychiatrist: 
cognitive impairment was found in 12 (21%) patients; 
asthenic syndrome in 10 (18%) patients; emotionally labile 
disorder in 5 (9%) patients; asthenic neurosis and mild 
somatoform dysfunction of the autonomic nervous system in 
3 (5%) patients; each of mixed anxiety-depressive disorder, 
moderate depression, histrionic personality disorder and 
anxiety disorder were found in one patient; and 
19 (34%) patients had no somatopsychic disorders. 
The utility of questionnaires generally used to detect 
somatopsychic disorders in COPD patients was assessed with 
standard operating characteristics of diagnostic models: 
sensitivity, specifity, area under ROC curve (AUC) showing 
the correctly classified cases to misclassified cases ratio. AUC 
allows to compare the utility of detection of pathologies by 
using a range of alternative diagnostic systems, which means 
it measures how well a particular parameter can distinguish 
patients of two diagnostic groups (in our study these two 
groups were presence/absence of mental disorders). A guide 
for assessing the utility of a method based on its AUC is as 
follows: 0.9–1.0 = excellent; 0.8–0.9 = good; 0.7–0.8 = fair; 
0.6–0.7 = poor; 0.5–0.6 = fail [37, 39]. 
The highest sensitivity (>75%) was determined for the 
HADS-depression, HADS-anxiety, and PHQ-9 questionnaires 
while BDI-SF had the lowest sensitivity. BDI-SF had the best 
specificity (>80%). HADS-depression (AUC=0.760, p=0.000) 
and HADS-anxiety had the highest operational characteristics 
(AUC=0.724, p=0.032). According to a rough guide for 
classifying AUC, the diagnostic accuracy of these 
questionnaire methods is fair. STAI-state anxiety and STAI-
trait anxiety showed lower and inaccurate levels of the 
operating characteristics (Fig. 1, 2, 3). 
 
 
 
Fig 1: Results of PHQ-9 and BDI-SF ROC-analysis 
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Fig 2: Results of HADS-depression and HADS-anxiety ROC-analysis 
 
 
 
Fig 3: Results of STAI-state anxiety and STAI- trait anxiety ROC-analysis 
 
No significant differences were found between all ROC-
curves and the best operating characteristics were confirmed 
for HADS-depression and HADS-anxiety (Fig. 4). 
 
 
 
Fig 4: Comparison of psychodiagnostic scales ROC-curves to assess 
presence of somatopsychic disorders in COPD patients 
 
Thought the questionnaires we used had been designed to 
identify patients with depression and anxiety, most of those 
scales helped us establish with certain degree of probability 
presence or absence of mental disorders without verification 
of clinical diagnosis which can only be performed by a 
psychiatrist. ROC-analysis allowed us to determine that the 
results received with the HADS (HADS-depression and 
HADS-anxiety) had the greatest diagnostic value for detection 
of somatopsychic disorders in COPD patients. This 
questionnaire has some other advantages over the rest of the 
scales. Firstly, the HADS was designed to assess changes in 
the mental state of patients with somatic complaints, 
including persons suffering from COPD. Accordingly, it takes 
into account the specific characteristics of patients with 
somatic disorders: the HADS contains minimum questions 
about symptoms that can be typical for older patients and be 
similar to those of somatic conditions, including COPD. 
Secondly, the HADS helps identify signs of depression and 
anxiety, which means it has wider diagnostic capabilities. 
Thirdly, the severity of symptoms is assessed by both their 
duration and intensity when the HADS is used, which reduces 
the risk that patient responses are affected by an underlying 
chronic condition having long-term effects on a person’s 
mental health. Fourthly, the HADS is easy to use by both 
patients and healthcare professionals for analysis of the 
collected data. 
 
Conclusions 
1. Somatopsychic disorders found in COPD patients can be 
of various nature which goes beyond depression and 
anxiety, and it requires more than using questionnaires to 
establish each of those disorders. 
2. The HADS has certain advantages over the rest of the 
questionnaires that can be used to detect somatopsychic 
disorders in COPD patients as was confirmed by using 
ROC-analysis. 
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